Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Buprenorphine hydrochloride

Available from:

Animalcare Limited

ATC code:

QN02AE01

INN (International Name):

Buprenorphine hydrochloride

Dosage:

0.3 milligram(s)/millilitre

Pharmaceutical form:

Solution for injection

Prescription type:

VPO: Veterinary Practitioner Only as defined in relevant national legislation

Therapeutic group:

Cats, Dogs

Therapeutic area:

buprenorphine

Therapeutic indications:

Neurological Preparations

Authorization status:

Authorised

Authorization date:

2008-05-16

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Each ampoule contains:
Buprenorphine 0.3 mg/ml as buprenorphine hydrochloride.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dog
Post-operative analgesia.
Potentiation of the sedative effects of centrally-acting agents.
Cat
Post-operative analgesia.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dog
Post-operative analgesia.
Potentiation of the sedative effects of centrally-acting agents.
Cat
Post-operative analgesia.
4.3 CONTRAINDICATIONS
The product should not be used pre-operatively for caesarean section
(see Section 4.7).
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_2_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_3_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_5_
_5_
_4_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Buprenorphine may occasionally cause significant respiratory
depression and, as with other opioid drugs, care should
be taken when treating animals with impaired respiratory function or
animals that are receiving drugs that can cause
respiratory depression.
Buprenorphine sh